B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 — Trials · CancerIndex

Clinical trials

Registered studies

39 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 18
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 6%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01190930	Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma	completed	Phase 3	9,350	Children's Oncology GroupNETWORK	7	May 28, 2026	clinicaltrials
NCT00720109	Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	completed	Phase 2 / Phase 3	63	National Cancer Institute (NCI)NIH	5	Apr 13, 2020